Pfizer/BioNTech Updated Covid-19 Vaccine Gets Canadian Approval
By Josh Beckerman
Pfizer and BioNTech said drug regulator Health Canada approved their updated Covid-19 vaccine, which will be available in the coming weeks.
Pfizer's Canadian business and Germany's BioNTech said the vaccine will be available in Canada as a single dose for people age 5 and up, regardless of Covid-19 vaccination history. For children 6 months through 4 years old, it is authorized as a three-dose series in those without a history of completion of a Covid-19 primary vaccination course, or as a single dose for those who have completed a primary vaccination course.
Last week, a committee from the European Medicine Agency recommended marketing authorization for the vaccine.
In August, the Food and Drug Administration approved the Pfizer/BioNTech vaccine, as well as Moderna's. The new vaccines target an offshoot of Omicron known as the KP.2 strain. Also approved was a Novavax vaccine that targets the JN.1 strain and has demonstrated cross-reactivity against JN.1 lineage viruses.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
September 24, 2024 14:17 ET (18:17 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks